Predict your next investment

HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Stage

Acquired | Acquired

About Haystack Sciences

Haystack Sciences Corporation is a small molecule discovery company developing a proprietary platform to discover novel treatments for human disease.On October 22nd, 2020, Haystack Sciences was acquired by insitro. Terms of the transaction were not disclosed.

Haystack Sciences Headquarter Location

California,

United States

Latest Haystack Sciences News

Insitro raises $400M for machine learning-powered drug discovery efforts

Mar 15, 2021

Mar 15, 2021 10:14am Temasek and Softbank Investment Advisors also joined the round, in addition to an undisclosed global investment group and a U.S. payer provider health system. (UCSF) The artificial intelligence-powered drug discovery company insitro has secured a mammoth funding round of $400 million, to carry forward its development efforts and Big Pharma partnerships with the likes of Gilead and Bristol Myers Squibb. The series C financing was led by the Canada Pension Plan Investment Board, also known as CPP Investments, with additional backing from Andreessen Horowitz, Casdin Capital, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital and Alexandria Venture Investments, as well as accounts managed by BlackRock and T. Rowe Price Associates. Temasek and Softbank Investment Advisors also joined the round, in addition to an undisclosed global investment group and a U.S. payer-provider health system. “For insitro, 2020 was a year of incredible growth and progress toward our founding vision of bringing the predictive powers of machine learning to drug discovery,” said founder and CEO Daphne Koller. “We built out and demonstrated the capabilities of our target discovery platform in our Gilead collaboration in NASH, receiving the first of our operational milestone payments, and put in place an outstanding collaboration with Bristol Myers Squibb in ALS; we also took a big step forward towards moving from targets to medicines through the acquisition of Haystack Sciences, a high throughput chemistry platform that enables [machine learning]-driven molecular design; and we recruited Dr. Roger Perlmutter to our board to help guide our drug discovery efforts,” Koller said. The new proceeds will be used to further expand the company’s efforts and development pipeline, including potentially in-licensed assets explored in insitro’s target and biomarker discovery work. The company picked up Haystack last October , through an acquisition focused on building large chemical libraries encoded by DNA sequences, to further collect massive datasets of small molecules that could be turned into therapies. Shortly thereafter, insitro announced a five-year collaboration project with Bristol Myers Squibb to bring machine learning programs to ALS and dementia research—collecting $50 million upfront and up to $2 billion if they’re successful.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Haystack Sciences Patents

Haystack Sciences has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Chemistry
  • Drug discovery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/8/2017

11/30/2021

Molecular biology, Biotechnology, Small nuclear RNA, Chemistry, Drug discovery

Grant

Application Date

6/8/2017

Grant Date

11/30/2021

Title

Related Topics

Molecular biology, Biotechnology, Small nuclear RNA, Chemistry, Drug discovery

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.